The price of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares last traded on Wall Street rose 22.50% to $17.15.
CYCC stock price is now 31.09% away from the 50-day moving average and -77.83% away from the 200-day moving average. The market capitalization of the company currently stands at $27.16M.
, while ‘Ladenburg Thalmann’ rates the stock as ‘Buy’
In other news, Lazar David E., Interim CEO sold 194,628,820 shares of the company’s stock on Feb 26 ’25. The stock was sold for $5,507,996 at an average price of $0.03. Upon completion of the transaction, the Interim CEO now directly owns 0 shares in the company, valued at $0.0. A total of 0.00% of the company’s stock is owned by insiders.
During the past 12 months, Cyclacel Pharmaceuticals Inc has had a low of $3.08 and a high of $597.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.60, and a quick ratio of 5.60. The fifty day moving average price for CYCC is $13.0886 and a two-hundred day moving average price translates $77.3774 for the stock.
The latest earnings results from Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was released for 2025-03-31. The net profit margin was -59607.14% and return on equity was -1949.77% for CYCC.
